Friday, June 19, 2026

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,771
Drugs linked 4,798

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 330 of 1,261
  1. US 11058688

    Imidazopiperazine inhibitors of transcription activating proteins

    The Board of Regents of the University of Texas System · Granted Jul 13, 2021 · Expires Jul 8, 2041

    granted
  2. US 11059896

    Stabilized formulations containing anti-interleukin-4 receptor (IL-4R) antibodies

    REGENERON PHARMACEUTICALS, INC. · Granted Jul 13, 2021 · Expires Jul 8, 2041

    granted
  3. US 11059907

    Antibodies that bind Notum Pectinacetylesterase

    LEXICON PHARMACEUTICALS, INC. · Granted Jul 13, 2021 · Expires Jul 8, 2041

    granted
  4. US 11059879

    Chimeric antigen receptor molecules and uses thereof

    The Board of Regents of the University of Texas System · Granted Jul 13, 2021 · Expires Jul 8, 2041

    granted
  5. US 11058802

    Anti-adhesive barrier membrane using alginate and hyaluronic acid for biomedical applications

    The Board of Regents of the University of Texas System · Granted Jul 13, 2021 · Expires Jul 8, 2041

    granted
  6. US 11058722

    Chimeric antigen receptor comprising a cartilage-oligomeric matrix protein (comp) coiled-coil spacer domain

    AUTOLUS LIMITED · Granted Jul 13, 2021 · Expires Jul 8, 2041

    granted
  7. US 11058645

    Inhibition of respiratory complex III by ligands that interact with a regulatory switch

    The Regents of the University of California · Granted Jul 13, 2021 · Expires Jul 8, 2041

    granted
  8. US 11059780

    Substituted pyrrolidine compound and use thereof

    Takeda Pharmaceutical Company Limited · Granted Jul 13, 2021 · Expires Jul 8, 2041

    granted
  9. US 11060089

    Antisense oligomers and methods of using the same for treating diseases associated with the acid alpha-glucosidase gene

    Sarepta Therapeutics, Inc. · Granted Jul 13, 2021 · Expires Jul 8, 2041

    granted
  10. US 11052057

    Use of cysteamine and derivatives thereof to suppress tumor metastases

    The United States of America as Represented by the Secretary, Dept. of Health and Human Services · Granted Jul 6, 2021 · Expires Jul 1, 2041

    granted
  11. US 11052144

    Methods of tumor vaccination

    DCPRIME B.V. · Granted Jul 6, 2021 · Expires Jul 1, 2041

    granted
  12. US 11053262

    Heterocyclic amide compounds having RORyT inhibitory action

    Takeda Pharmaceutical Company Limited · Granted Jul 6, 2021 · Expires Jul 1, 2041

    granted
  13. US 11052064

    Compositions, methods and systems for the treatment of cutaneous disorders

    Verrica Pharmaceuticals Inc. · Granted Jul 6, 2021 · Expires Jul 1, 2041

    granted
  14. US 11053310

    Antibodies for the treatment of cancers

    The Regents of the University of California · Granted Jul 6, 2021 · Expires Jul 1, 2041

    granted
  15. US 11053314

    Methods to eliminate cancer stem cells by targeting CD47

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Jul 6, 2021 · Expires Jul 1, 2041

    granted
  16. US 11052073

    Sphingosine kinase 2 inhibitor for treating coronavirus infection

    RedHill Biopharma Ltd. · Granted Jul 6, 2021 · Expires Jul 1, 2041

    granted
  17. US 11052075

    Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid and administration thereof

    Vertex Pharmaceuticals Incorporated · Granted Jul 6, 2021 · Expires Jul 1, 2041

    granted
  18. US 11051499

    Genetically modified mice and engraftment

    REGENERON PHARMACEUTICALS, INC. · Granted Jul 6, 2021 · Expires Jul 1, 2041

    granted
  19. US 11053495

    Multi-targeted single entity conjugates

    Alnylam Pharmaceuticals, Inc. · Granted Jul 6, 2021 · Expires Jul 1, 2041

    granted
  20. US 11053484

    Genetically-modified T cells comprising a modified intron in the T cell receptor alpha gene

    Precision BioSciences, Inc. · Granted Jul 6, 2021 · Expires Jul 1, 2041

    granted
  21. US 11054423

    Antibody-mediated neutralization of ebolaviruses

    The Board of Regents of the University of Texas System · Granted Jul 6, 2021 · Expires Jul 1, 2041

    granted
  22. US 11053309

    Methods for treating active eosinophilic esophagitis

    REGENERON PHARMACEUTICALS, INC. · Granted Jul 6, 2021 · Expires Jul 1, 2041

    granted
  23. US 11053290

    Modified Tamm-Horsfall protein and related compositions and methods of use

    The United States Government as Represented by the Department of Veterans Affair · Granted Jul 6, 2021 · Expires Jul 1, 2041

    granted
  24. US 11053284

    Process for the preparation of cyclic depsipeptides

    OnKure, Inc. · Granted Jul 6, 2021 · Expires Jul 1, 2041

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.